Asia-Pacific Nasal Spray Market, By Product Type (Decongestion Nasal Spray, Steroid Nasal Spray, Salt Water Solution/Saline Nasal Spray, and Others), Container Design (Pump Bottles and Pressurized Canisters), Dosage Form (Multi Dose, Unit/Single Dose, and Bi Dose), Therapeutic Class (Antihistamine, Nasal Steroid, Mast Cell Inhibitor, and Anticholinergic), Application (Nasal Congestion, Allergic and Non-Allergic Rhinitis, Central Nervous System Disorders, Vaccination, and Others), Prescription/Availability (Over The Counter and Prescribed), End User (Home Care Settings, Hospitals, Clinics, and Community Health Care)- Industry Trends and Forecast to 2030.
Asia-Pacific Nasal Spray Market Analysis and Insights
Allergic rhinitis is a major health problem that causes problems in more than 500 million people in the world. It has symptoms such as nasal congestion, snoring, postnasal drip, and cough, reduction in the sense of smell, headache, and others for months or years in almost half of the patients on earth. These symptoms can also affect the quality of life of patients.
A nasal spray is a device widely used as a system in nasal drug delivery to treat major allergy problems such as nasal congestion, infections, itchy or watery eyes, runny nose, chest congestion, cough, wheezing, labored breathing, shallow breathing, and others. Some other diseases which also include nasal polyps, inflammatory bowel disease, kidney-related problems, and others. Administration of medicines or drugs by the nose in dosage form with the help of spray is a non-invasive technique that provides rapid action of a drug in the body of patients. A nasal spray is one of the most cost-effective, does not require invasion, is easy to use and self-administered, and has high patient compliance. Therefore nasal drug delivery is one of the popular routes of drug administration in recent times and has a strong growth opportunity.
Nasal sprays are available in the market as over-the-counter (OTC) or prescription drugs for the treatment of nasal diseases such as nasal allergies, blocked or stuffy nose, chronic sinus, allergic rhinitis, and other problems associated with the nose. These sprays are available in the market as a pump or as canisters.
Data Bridge Market Research analyzes that the Asia-Pacific nasal spray market is expected to reach a value of USD 6,248.16 million by 2030, at a CAGR of 7.1% during the forecast period.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Year |
2021 (Customizable to 2015-2020) |
|
Quantitative Units |
Revenue in Million, Volumes in Units, and Pricing in USD |
|
Segments Covered |
Product Type (Decongestion Nasal Spray, Steroid Nasal Spray, Salt Water Solution/Saline Nasal Spray, and Others), Container Design (Pump Bottles and Pressurized Canisters), Dosage Form (Multi Dose, Unit/Single Dose, and Bi Dose), Therapeutic Class (Antihistamine, Nasal Steroid, Mast Cell Inhibitor, and Anticholinergic), Application (Nasal Congestion, Allergic and Non-Allergic Rhinitis, Central Nervous System Disorders, Vaccination, and Others), Prescription/Availability (Over The Counter and Prescribed), End User (Home Care Settings, Hospitals, Clinics, and Community Health Care) |
|
Countries Covered |
China, Japan, India, Australia, South Korea, Malaysia, Thailand, Singapore, Indonesia, Philippines, and Rest of Asia-Pacific |
|
Market Players Covered |
EMERGENT, Cipla Inc., Sandoz International GmbH (A Part of Novartis), Aytu Health (A subsidiary of Aytu BioPharma, Inc.), Bayer AG, GlaxoSmithKline plc., Assertio Therapeutics, Inc., Aurena Laboratories., J Pharmaceuticals, St. Renatus., Ultratech India Limited, Catalent, Inc., Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd), Pfizer Inc., Viatris Inc., LEEFORD HEALTHCARE LTD, and Aishwarya Group among others |
Market Definition
Nasal sprays are devices that help in the delivery of the drug through the nose in the nasal cavity to treat allergies and other problems related to brain inflammation, diabetes, dental problems, and the central nervous system. Allergy is a condition in which the immune system of the body reacts abnormally to a foreign substance. Nasal spray drug products consist of therapeutically active ingredients or drug substances in the form of solution or suspension of excipients.
There are different types of nasal spray available in the market, such as decongestion nasal spray, saline nasal spray, and steroid nasal spray. Decongestants are devices with drugs for the treatment of nasal congestion and provide short-term relief from a blocked nose. The decongestion nasal spray consists of drugs that open up the airways of the nasal part and helps in the breathing process.
During the cold and dry winter season, saline nasal sprays are used to avoid problems related to a stuffy nose. These devices are used to treat sinusitis, nasal crusting, and thin secretions of liquid from the nose, which are formed due to bacterial infection and lead to the dryness of the nasal area. This device helps in cleaning the nasal passage and mucus present in that area due to cold.
Asia-Pacific Nasal Spray Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
DRIVER
- Increase in Infection and Allergic Cases
Allergy is a condition that makes the immune system weaken, and the immune system reacts abnormally to a foreign substance. Allergies have many forms, such as Allergic Rhinitis (AR), and this affects nearly 40 to 50 million people in the U.S. Some allergies may interfere with day-to-day activities and the quality of life.
Due to the increase in population, urbanization, and industrialization has increased tremendously, which has led to a rise in allergen. This allergen is responsible for allergies or infectious diseases in many people.
Thus, the rise in the prevalence of allergic diseases such as AR has led to an increase in the demand for nasal sprays, which is expected to drive market growth in the coming years.
RESTRAINT
- Adverse Effects of Using Nasal Sprays
Many people opt for nasal sprays in order to get relief from a runny and stuffy nose, but using a nasal spray for a longer period of time causes several side effects. Steroid nasal sprays, also called corticosteroid nasal sprays, are anti-inflammatory medicines that are sprayed into the nose. They can be used to treat a range of conditions, including hay fever, sinusitis, non-allergic rhinitis, and nasal polyps. Some steroid nasal sprays are available to buy from pharmacies and shops, while others are only available on prescription.
Using nasal sprays for a prolonged period of time can lead to bleeding from the nose and even headaches. Some may experience other side effects, such as addiction or even congestion.
If one is taking a high dose for a long time, there is also a small chance one could get some of the side effects of steroid tablets, such as increased appetite, mood changes, and difficulty sleeping.
Thus, the adverse effects of nasal sprays are expected to restrain the market growth.
OPPORTUNITY
-
Expanding Therapeutic Applications for Nasal Sprays
Intranasal administration provides various useful options for the local and systemic delivery of diverse therapeutic agents for the treatment of problems such as allergies, respiratory diseases, and many others.
A nasal spray is one of the recently developed products, such as OptiNose and ViaNase, that helps to enable the targeting of formulations to a specific area of the site in the nasal cavity in humans.
Nasal therapy has been known as a form of treatment in Indian medicine for decades. It is also called “NASAYA KARMA” in Ayurvedic systems in Indian medicine.
The nasal spray consists of one or more than one therapeutically active ingredients in the form of suspension or solution in a non-pressurized dispenser. The most common allergy is AR.
Apart from respiratory problems, there are other therapeutic areas such as orthopedic, renal, and many other areas, where the nasal spray is playing important role in treating and curing such problems. In the future, other treatments may be developed that can help in the treatment of other problems easily.
CHALLENGE
- Regulatory Hurdles
Nasal drug delivery can be evaluated by many regulatory agencies, such as the U.S. FDA and the European Medicines Agency (EMA). These agencies provide a set of guidelines and regulations for any product before it is launched in the market. They allow performing various in vitro test methods for determining the characterization of nasal drug products and that should come in an acceptable range as given by such regulatory bodies.
Nasal spray can be designed as per the dose requirement of drug substances for patients suffering from nasal or any other issues. Some aspects of nasal sprays may be exceptional in the case of formulation, manufacturing, container closure system, stability, controls of critical steps, intermediates, and drug products. These aspects should be measured carefully while developing a program of nasal spray. Because of these changes ability of the product to treat patients may get affected.
Strict rules and regulations for the product for nasal spray manufacturing are more challenging for the manufacturer to get approval from regulatory agencies. The spray characteristics can be influenced by the design of the device, and by the handling of the device. Performing such tests to get the perfect result, that is, an acceptable range as given by the regulatory body, is more challenging in nasal spray manufacturing.
Post-COVID-19 Impact Analysis on the Asia-Pacific Nasal Spray Market
COVID-19 had a significant impact on the generic drug market for inhalation and nasal spray, as one of the main symptoms associated with COVID-19 is shortness of breath. The demand for inhalation and nasal spray increased during the pandemic.
For instance,
- According to a MedComm journal article published in 2021, nasal sprays demonstrated the ability to be an effective COVID-19 treatment and vaccine option
Spray formulations that may inactivate SARS-CoV-2 or restrict its entry into cells were thought to be beneficial in preventing viral spread to the lungs or surrounding people. Relaxed lockdowns and the resumption of healthcare practices are expected to accelerate market growth in the post-pandemic era. COVID-19 patients are still experiencing long-term side effects such as shortness of breath.
Recent Developments
- In January 2023, Viatris Inc. (NASDAQ: VTRS), a Asia-Pacific healthcare company, today announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. This acquisition would help the company in its business expansion.
- In March 2023, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd, announced the launch of additional strengths for the generic version of Revlimid1 (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the U.S. This product launch would help the company in its product portfolio expansion.
Asia-Pacific Nasal Spray Market Scope
The Asia-Pacific nasal spray market is segmented into seven notable segments on the basis of product type, container design, dosage form, therapeutic class, application, prescription/ availability, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
PRODUCT TYPE
- DECONGESTION NASAL SPRAY
- STEROID NASAL SPRAY
- SALT WATER SOLUTION/ SALINE NASAL SPRAY
- OTHERS
On the basis of product type, the market is segmented into decongestion nasal spray, salt water solution/saline nasal spray, steroid nasal spray, and others.
CONTAINER DESIGN
- PUMP BOTTLES
- PRESSURIZED CANISTERS
On the basis of container design, the market is segmented into pressurized canisters and pump bottles.
DOSAGE FORM
- MULTI DOSE
- UNIT/SINGLE DOSE
- BI DOSE
On the basis of dosage form, the market is segmented into unit/single dose, bi dose, and multi dose.
THERAPEUTIC CLASS
- ANTIHISTAMINE
- NASAL STEROIDS
- MAST CELL INHIBITOR
- ANTICHOLINERGIC
On the basis of therapeutic class, the market is segmented into antihistamine, nasal steroids, mast cell inhibitor, and anticholinergic.
APPLICATION
- NASAL CONGESTION
- ALLERGIC AND NON-ALLERGIC RHINITIS
- CENTRAL NERVOUS SYSTEM DISORDERS
- VACCINATION
- OTHERS
On the basis of application, the market is segmented into nasal congestion, allergic and non-allergic rhinitis, central nervous system disorders, vaccination, and others.
PRESCRIPTION/AVAILABILITY
- OVER THE COUNTER
- PRESCRIBED
On the basis of prescription/availability, the market is segmented into over the counter and prescribed.
END USER
- HOME CARE SETTINGS
- HOSPITALS
- CLINICS
- COMMUNITY HEALTH CARE
On the basis of end user, the market is segmented into home care settings, hospitals, clinics, and community health care.
Asia-Pacific Nasal Spray Market Regional Analysis/Insights
The Asia-Pacific nasal spray market is segmented into seven notable segments on the basis of product type, container design, dosage form, therapeutic class, application, prescription/ availability, and end user.
The countries covered in this market report are China, Japan, India, Australia, South Korea, Malaysia, Thailand, Singapore, Indonesia, Philippines, and the rest of Asia-Pacific.
In 2023, China is dominating the Asia-Pacific nasal spray market due to increasing customer inclinations toward nasal spray.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Nasal Spray Market Share Analysis
The Asia-Pacific nasal spray market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.
Some of the major market players operating in the Asia-Pacific nasal spray market are EMERGENT, Cipla Inc., Sandoz International GmbH (A Part of Novartis), Aytu Health (A subsidiary of Aytu BioPharma, Inc.), Bayer AG, GlaxoSmithKline plc., Assertio Therapeutics, Inc., Aurena Laboratories., J Pharmaceuticals, St. Renatus., Ultratech India Limited, Catalent, Inc., Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd), Pfizer Inc., Viatris Inc., LEEFORD HEALTHCARE LTD, and Aishwarya Group among others.
SKU-
